medigraphic.com
Colegio de Medicina Interna de México.

2012, Number 4

<< Back Next >>

Med Int Mex 2012; 28 (4)

Prevalence of few atherogenic lipid phenotypes in patients with HIV, with and without antiretroviral therapy

Castro-Sansores C, Guerrero-Flores A, Santos-Rivero A

Language: Spanish
References: 24
Page: 336-341
PDF size: 76.14 Kb.


ABSTRACT

Background: The importance of the lipids alterations is in the strong relation that exists between these and the cardiovascular disease in the general population and is not possible to hope that they are different in the patients with the human immunodeficiency virus (HIV). In this study we determined the lipid phenotypes (Fredrickson Classification) in a group of Mexican patients with the HIV infection.
Methodology: A cross-sectional study was realised. The patients were taken care of in 8 specialized centers in the attention of patients with the infection by the HIV/Aids of four states of south-east of Mexico (Chiapas, Quintana Roo, Tabasco and Yucatan). To all of them, the lipid profile was determined and according to the Fredrickson classification the phenotypes were defined in: IIa (only with C-LDL › 160 mg/dL); phenotype IIb (C-LDL › 160 mg/dL more C-VLDL › 35 mg/dL) and phenotype IV (only with C-VLDL › 35 mg/dL).
Results: We studied 289 patients, 35 (12%) women and 254 (88%) men. The average of age of the group was of 39 (20-73) years. The time average to be diagnosed with the HIV infection was of 6,1 years. One hundred ninety seven (68%) patient had some hyperlipidaemia (total cholesterol › 200 mg/dL and/or triglycerides › 200 mg/dL). According to the phenotypes of the Fredrickson classification, 6 (2,1%) patient had the IIa phenotype, 42 (14,5%) the IIb phenotype and 149 (51,6%) IV phenotype.
Conclusions: Our observations show that more than half of this group of patients with the HIV infection, they had one hyperlipidaemia of phenotype IV in the Fredrickson classification, phenotype considered with low atherogenic potential.


REFERENCES

  1. Grunfeld C, Kotler DP, Hamadeh R, Tierney A, Wang J, Pierson RN. Hypertriglyceridemia in the acquired immunodeficiency síndrome. Am J Med 1989;86:27-31.

  2. Hoyert DL, Arias E, Smith BL, Murphy SL, Kochanek KD. Deaths: final data for 1999. Natl Vital Stat Rep 2001;49:1-134.

  3. Klein D, Hurley LB, Quesenberry CP Jr, Sidney S. Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? J Acquir Immune Defic Syndr 2002;30:471-477.

  4. Behrens G, Schmidt H, Meyer D, Stoll M, Schmidt RE. Vascular complications associated with the use of HIV protease inhibitors. Lancet 1998;351:1958.

  5. Henry K, Melroe H, Huebesch J, Hermundson J, Simpson J. Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalities. Lancet 1998;352:1031–1032.

  6. Juette A, Schwenk A, Franzen C, Romer K, Diet F, Diehl V, et al. Increasing morbidity from myocordial infarction during HIV protease inhibitor treatment? AIDS 1999 13:1796–1797.

  7. Henry K, Melroe H, Huebsch J, Hermundson J, Levine C, Swensen L, et al. Severe premature coronary artery disease with protease inhibitors. Lancet 1998;351:1328.

  8. Castro-Sansores CJ, Santos-Rivero A, Lara-Perera D, González-Martínez P, Alonso-Salomón G, Góngora-Biachi R. Hiperlipidemia e intolerancia a la glucosa en un grupo de pacientes infectados con VIH que reciben terapia antirretrovírica hiperactiva. Salud Publica Mex 2006;48:193-199.

  9. Bonnet E, Ruidav ets JB, Tuech J, Ferrie`res J, Collet X, Fauvel J, et al. Apoprotein C-III and E-containing lipoparticles are markedly increased in HIV-infected patients treated with protease inhibitors: association with the development of lipodystrophy. J Clin Endocrinol Metab 2001;86:296–302.

  10. Brunzell JD, Albers JJ, Chait A, Grundy SM, Groszek E, McDonald GB, et al. Plasma lipoproteins in familial combined hyperlipidemia and monogenic familial hypertriglyceridemia. J Lipid Res 1983;24:147–155.

  11. Voors-Pette C, de Bruin TWA. Excess coronary heart disease in familial combined hyperlipidemia, in relation to genetic factors and central obesity. Atherosclerosis 2001;157:481–489.

  12. Brunzell JD, Schrott HG, Motu lsky AG, Biermann EL. Myocardial infarctions in the familial forms of hypertriglyceridemia. Metabolism 1976;25:313–320.

  13. Chait A, Brunzell JD. Severe hypertriglyceridemia: Role of familial and acquired forms. Metabolism 1983;32:209.

  14. Castro-Sansores C, Guerrero-Flores A, Santos-Rivero A, Sarmiento-Coutiño C, Valencia-Serrano N, Bolaños-Caldelas E. Comparación de tres métodos para la estimación del riesgo cardiovascular en una población de pacientes con infección por VIH. Med Int Mex 2011;27:439-445.

  15. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999;353:2093–2099.

  16. The Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination of antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003;349:1993-2003.

  17. Bozzette SA, Ake CF, Tam HK, Chang SW, Louis TA. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 2003;348:702-710.

  18. Duong M, Cottin Y, Piroth L, Fargeot A, Lhuiller I, Bobillier M, et al. Exercise stress testing for detection of silent myocardial ischemia in human immunodeficiency virus-infected patients receiving antiretroviral therapy. Clin Infect Dis 2002;34:523-528.

  19. Mauss S, Stechel J, Willers R, Schmutz G, Berger F, Richter WO. Differentiating hyperlipidaemia associated with antiretroviral therapy. AIDS 2003;17:189–194.

  20. Purnell JQ, Zambon A, Knopp RH, Pizzuti DJ, Achari R, Leonard JM, Locke C, Brunzell JD. Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects. AIDS 2000;14:51-57.

  21. Rader DJ. Trastornos del metabolismo de las lipoproteínas. En: Harrison Principios de Medicina Interna. 16ª edición, Vol. III, México, D.F. 2005; p:2516-2530.

  22. Castro-Sansores C, Santos-Rivero A, Guerrero-Flores A, Rodríguez-Sánchez R, y col. Riesgo cardiovascular en pacientes con VIH. Med Int Mex 2008;24:284-288.

  23. Bergersen BM, Sandvik L, Bruun JN, Tonstad S. Elevated Framingham risk score in HIV-positive patients on highly active antiretroviral therapy: results from a Norwegian study of 721 subjects. Eur J Clin Microbiol Infect Dis 2004;23:625-630.

  24. Santos J, Palacios R, González M, Ruiz J, Márquez M. Atherogenic lipid profile and cardiovascular risk factors in HIV-infected patients (Netar Study). International Journal of STD & AIDS 2005;16:677-680.




2020     |     www.medigraphic.com